Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. (FOLD) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
fold · stock forecast · 24 analysts (3M) · FMP · updated May 4, 2026
Analyst Rating & Consensus
Based on 24 Wall Street analysts in the past 3 months
Buy
24 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$14.50
Consensus
$14.50
+0.1% upside
Low
$14.50
Median: $14.5 · Last Close: $14.49
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
RangingAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $14.48 | ↓ 0.09% |
1-day model range: $14.47–$14.48. Peak: $14.48 (-0.09%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $15 | +6.5% |
| 2028 | $16 | +10.6% |
| 2029 | $16 | +13.1% |
| 2030 | $17 | +14.7% |
| 2031 | — | +15.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · FOLD · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-01-22 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-12-29 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2025-12-22 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2025-12-19 | Needham | Downgrade ↓ | Buy→Hold |
| 2025-12-19 | Cantor Fitzgerald | Downgrade ↓ | Overweight→Neutral |
| 2025-11-06 | JP Morgan | Maintains | Overweight→Overweight |
| 2025-11-05 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2025-09-18 | Needham | Upgrade ↑ | Hold→Buy |
| 2025-07-17 | Morgan Stanley | Upgrade ↑ | Equal Weight→Overweight |
| 2025-05-02 | UBS | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Amicus Therapeutics, Inc. (FOLD) stock. Of the recent 80 rating actions, 17 were upgrades and 13 were downgrades. 24 analysts currently cover FOLD.
Analyst Recommendation Trends
FOLD analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$754M
↓ 31.2% YoY
Revenue Next Year
$896M
↑ 18.9% YoY
EPS This Year
$0.36
EPS Next Year
$0.64
↑ 79.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast FOLD EPS of $0.36 for the current fiscal year, based on estimates from 1 analysts. The FOLD revenue forecast is $754M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The FOLD stock forecast is supported by two independent data sources: analyst consensus ratings from 24 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FOLD price target is $14.50 (+0.1% upside), with an analyst consensus of Buy.
The FOLD short-term stock prediction for tomorrow is $14.48 (-0.09%). The FOLD stock price prediction for 2027 estimates an average of $15. The FOLD stock prediction for 2030 projects a range of $17–$17.
Amicus Therapeutics, Inc. trades on NASDAQ under the ticker FOLD. The FOLD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
FOLD forecast · 8 questionsAccording to 24 Wall Street analysts, the average 12-month FOLD price target is $14.50, with a high forecast of $14.50 and a low of $14.50. The median price target is shown in the chart above when available. This implies +0.1% potential upside from the current price of $14.49.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.